{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:07:28Z","timestamp":1778771248693,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007833","name":"Hamad Medical Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004397","name":"Ministry of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EClinicalMedicine"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.eclinm.2021.100861","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T05:25:53Z","timestamp":1619587553000},"page":"100861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":157,"special_numbering":"C","title":["SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0790-0506","authenticated-orcid":false,"given":"Laith J.","family":"Abu-Raddad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiam","family":"Chemaitelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Coyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel A.","family":"Malek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayeda A.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmin A.","family":"Mohamoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8971-5149","authenticated-orcid":false,"given":"Shameem","family":"Younuskunju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houssein H.","family":"Ayoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaina","family":"Al Kanaani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Einas","family":"Al Kuwari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeel A.","family":"Butt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Jeremijenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anvar Hassan","family":"Kaleeckal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Nizar","family":"Latif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riyazuddin Mohammad","family":"Shaik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanan F.","family":"Abdul Rahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gheyath K.","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi M.","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Ghaith","family":"Al Kuwari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamad Eid","family":"Al Romaihi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed H.","family":"Al-Thani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullatif","family":"Al Khal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Bertollini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2021.100861_bib0001","unstructured":"World Health Organization (WHO). WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Available from: https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020. Accessed on March 14, 2020."},{"key":"10.1016\/j.eclinm.2021.100861_bib0002","doi-asserted-by":"crossref","unstructured":"De Walque D, Friedman J, Gatti RV, Mattoo A. How two tests can help contain COVID-19 and revive the economy. Available from: http:\/\/documents.worldbank.org\/curated\/en\/766471586360658318\/pdf\/How-Two-Tests-Can-Help-Contain-COVID-19-and-Revive-the-Economy.pdf. Accessed on April 16, 2020. Research & Policy Briefs, World Bank Malaysia Hub 2020.","DOI":"10.1596\/33583"},{"key":"10.1016\/j.eclinm.2021.100861_bib0003","unstructured":"Kaplan J, Frias L, McFall-Johnsen M. A third of the global population is on coronavirus lockdown. Available from: https:\/\/www.businessinsider.com.au\/countries-on-lockdown-coronavirus-italy-2020-3. Accessd on: April 25, 2020. Business Insider Australia 2020."},{"key":"10.1016\/j.eclinm.2021.100861_bib0004","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijsu.2020.04.018","article-title":"The socio-economic implications of the coronavirus pandemic (COVID-19): a review","volume":"78","author":"Nicola","year":"2020","journal-title":"Int J Surg"},{"key":"10.1016\/j.eclinm.2021.100861_bib0005","article-title":"Assessment of the risk of SARS-CoV-2 reinfection in an intense re-exposure setting","author":"Abu-Raddad","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eclinm.2021.100861_bib0006","article-title":"Genomic evidence for reinfection with SARS-CoV-2: a case study","author":"Tillett","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.eclinm.2021.100861_bib0007","article-title":"COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing","author":"To","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eclinm.2021.100861_bib0008","article-title":"Symptomatic SARS-CoV-2 reinfection by a phylogenetically distinct strain","author":"Van Elslande","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.eclinm.2021.100861_bib0009","doi-asserted-by":"crossref","DOI":"10.2139\/ssrn.3686174","article-title":"COVID-19 re-infection by a phylogenetically distinct SARS-CoV-2 variant, first confirmed event in South America","author":"Prado-Vivar","year":"2020","journal-title":"SSRN"},{"key":"10.1016\/j.eclinm.2021.100861_bib0010","unstructured":"Planning and Statistics Authority- State of Qatar. Qatar Monthly Statistics. Available from: https:\/\/www.psa.gov.qa\/en\/pages\/default.aspx. Accessed on: may 26,2020. 2020."},{"key":"10.1016\/j.eclinm.2021.100861_bib0011","unstructured":"Planning and Statistics Authority-State of Qatar. The Simplified Census of Population, Housing & Establishments. Available from: https:\/\/www.psa.gov.qa\/en\/statistics\/Statistical%20Releases\/Population\/Population\/2018\/Population_social_1_2018_AE.pdf. Accessed on: April 2, 2020. 2019."},{"issue":"1","key":"10.1016\/j.eclinm.2021.100861_bib0012","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1038\/s41598-021-85428-7","article-title":"Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic","volume":"11","author":"Abu-Raddad","year":"2021","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.eclinm.2021.100861_bib0013","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040428","article-title":"Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar, 28 February\u201318 April 2020","volume":"10","author":"Al Kuwari","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.eclinm.2021.100861_bib0014","article-title":"Seroprevalence of SARS-CoV-2 infection in the craft and manual worker population of Qatar","author":"Al-Thani","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.eclinm.2021.100861_bib0015","doi-asserted-by":"crossref","first-page":"05005","DOI":"10.7189\/jogh.11.05005","article-title":"Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19","volume":"11","author":"Ayoub","year":"2021","journal-title":"J Glob Health"},{"key":"10.1016\/j.eclinm.2021.100861_bib0016","article-title":"Evidence for and level of herd immunity against SARS-CoV-2 infection: the ten-community study","author":"Jeremijenko","year":"2021","journal-title":"Emerging Infectious Diseases (in press)"},{"key":"10.1016\/j.eclinm.2021.100861_bib0017","article-title":"SARS-CoV-2 seroprevalence in the urban population of Qatar: an analysis of antibody testing on a sample of 112,941 individuals","author":"Coyle","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.eclinm.2021.100861_bib0018","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.eclinm.2021.100861_bib0019","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2021.100861_bib0020","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","author":"Voysey","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2021.100861_bib0021","doi-asserted-by":"crossref","unstructured":"Ayoub HH, Chemaitelly H, Makhoul M, et\u00a0al. Epidemiological impact of prioritizing SARS-CoV-2 vaccination by antibody status: mathematical modeling analyses. BMJ Innov; Epub ahead of print: [31 March 2021]. doi:10.1136\/bmjinnov-2021-000677.","DOI":"10.1136\/bmjinnov-2021-000677"},{"key":"10.1016\/j.eclinm.2021.100861_bib0022","unstructured":"Hamad Medical Corporation. National SARS-CoV-2 PCR testing, infection severity, and hospitalization database. 2020."},{"key":"10.1016\/j.eclinm.2021.100861_bib0023","unstructured":"World Health Organization. Clinical management of COVID-19. Available from: https:\/\/www.who.int\/publications-detail\/clinical-management-of-covid-19. Accessed on: May 31st 2020."},{"key":"10.1016\/j.eclinm.2021.100861_bib0024","unstructured":"World Health Organization. International guidelines for certification and classification (coding) of COVID-19 as cause of death. Available from: https:\/\/www.who.int\/classifications\/icd\/Guidelines_Cause_of_Death_COVID-19-20200420-EN.pdf?ua=1. Document Number: WHO\/HQ\/DDI\/DNA\/CAT. Accessed on June 1, 2020."},{"key":"10.1016\/j.eclinm.2021.100861_bib0025","article-title":"Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation","volume":"29","author":"Oved","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.eclinm.2021.100861_bib0026","article-title":"High-throughput extraction of SARS-CoV-2 RNA from nasopharyngeal swabs using solid-phase reverse immobilization beads","author":"Kalikiri","year":"2020","journal-title":"medRxiv"},{"issue":"22","key":"10.1016\/j.eclinm.2021.100861_bib0027","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1001\/jama.2020.8259","article-title":"Interpreting diagnostic tests for SARS-CoV-2","volume":"323","author":"Sethuraman","year":"2020","journal-title":"JAMA"},{"issue":"32","key":"10.1016\/j.eclinm.2021.100861_bib0028","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.25.32.2001483","article-title":"Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020","volume":"25","author":"Singanayagam","year":"2020","journal-title":"Euro Surveill"},{"issue":"3","key":"10.1016\/j.eclinm.2021.100861_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115130","article-title":"The importance of cycle threshold values in interpreting molecular tests for SARS-CoV-2","volume":"98","author":"Drew","year":"2020","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"7","key":"10.1016\/j.eclinm.2021.100861_bib0030","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1016\/S2666-5247(20)30120-8","article-title":"Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: an observational study","volume":"1","author":"Wajnberg","year":"2020","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.eclinm.2021.100861_bib0031","unstructured":"Cha S, Smith J. Explainer: South Korean findings suggest 'reinfected' coronavirus cases are false positives. Reuters Available from: https:\/\/wwwreuterscom\/article\/us-health-coronavirus-southkorea-explain-idUSKBN22J0HR. Accessed on: November 24, 2020."},{"key":"10.1016\/j.eclinm.2021.100861_bib0032","unstructured":"Bo-gyung K. Tests in recovered patients found false positives, not reinfections, experts say. The Korea Herald Available from: http:\/\/wwwkoreaheraldcom\/viewphp?ud=20200429000724. Accessed on November 24, 2020."},{"key":"10.1016\/j.eclinm.2021.100861_bib0033","series-title":"College station","article-title":"Statistical Software: release 16.1","year":"2019"},{"key":"10.1016\/j.eclinm.2021.100861_bib0034","unstructured":"Weill Cornell Medicine in Qatar. SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks. https:\/\/www.ncbi.nlm.nih.gov\/bioproject\/PRJNA698478\/. https:\/\/www.ncbi.nlm.nih.gov\/bioproject\/?term=PRJNA699251\/. 2021."},{"key":"10.1016\/j.eclinm.2021.100861_bib0035","article-title":"Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months","volume":"88","author":"Abu-Raddad","year":"2020","journal-title":"Infect Genet Evol"},{"issue":"4","key":"10.1016\/j.eclinm.2021.100861_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.06.043","article-title":"Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.eclinm.2021.100861_bib0037","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.cell.2020.06.040","article-title":"Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear","volume":"182","author":"Grubaugh","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.eclinm.2021.100861_bib0038","unstructured":"Planning and Statistics Authority- State of Qatar. Labor force sample survey. Available from: https:\/\/www.psa.gov.qa\/en\/statistics\/Statistical%20Releases\/Social\/LaborForce\/2017\/statistical_analysis_labor_force_2017_En.pdf. Accessed on: May 01, 2020. 2017."},{"key":"10.1016\/j.eclinm.2021.100861_bib0039","article-title":"SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates","author":"Seedat","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.eclinm.2021.100861_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)00575-4","article-title":"Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study","author":"Hansen","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2021.100861_bib0041","article-title":"Antibody status and incidence of SARS-CoV-2 infection in health care workers","author":"Lumley","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eclinm.2021.100861_bib0042","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2021.0366","article-title":"Association of SARS-CoV-2 seropositive antibody test with risk of future infection","author":"Harvey","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.eclinm.2021.100861_bib0043","article-title":"Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: june to November 2020","author":"Hall","year":"2021","journal-title":"medRxiv"},{"issue":"4","key":"10.1016\/j.eclinm.2021.100861_bib0044","doi-asserted-by":"crossref","first-page":"e13520","DOI":"10.1111\/eci.13520","article-title":"SARS-CoV-2 re-infection risk in Austria","volume":"51","author":"Pilz","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.eclinm.2021.100861_bib0045","article-title":"Risk of reinfection after seroconversion to SARS-CoV-2: a population-based propensity-score matched cohort study","author":"Leidi","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.eclinm.2021.100861_bib0046","article-title":"Reinfection rates among patients who previously tested positive for COVID-19: a retrospective cohort study","author":"Sheehan","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.eclinm.2021.100861_bib0047","doi-asserted-by":"crossref","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","author":"Dan","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.eclinm.2021.100861_bib0048","unstructured":"The Roche Group. Roche's COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark. Available from: https:\/\/www.roche.com\/media\/releases\/med-cor-2020-05-03.htm. Accessed on: June 5, 2020."},{"key":"10.1016\/j.eclinm.2021.100861_bib0049","unstructured":"Public Health England. Evaluation of Roche Elecsys AntiSARS-CoV-2 serology assay for the detection of anti-SARS-CoV-2 antibodies. Available from: https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/891598\/Evaluation_of_Roche_Elecsys_anti_SARS_CoV_2_PHE_200610_v8.1_FINAL.pdf. Accessed on June 5, 2020."},{"key":"10.1016\/j.eclinm.2021.100861_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(21)00662-0","article-title":"Risk of SARS-CoV-2 reinfection after natural infection","author":"Boyton","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2021.100861_bib0051","unstructured":"European Centre for Disease Prevention and Control. Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom \u201320 December 2020. Available from: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/SARS-CoV-2-variant-multiple-spike-protein-mutations-United-Kingdom.pdf. Accessed on: January 7, 2021. ECDC: Stockholm, 2020."}],"container-title":["EClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537021001413?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537021001413?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T19:06:17Z","timestamp":1762887977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537021001413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":51,"alternative-id":["S2589537021001413"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2021.100861","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.01.15.21249731","asserted-by":"object"}]},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy","name":"articletitle","label":"Article Title"},{"value":"EClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2021.100861","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100861"}}